GP方案治疗晚期非小细胞肺癌的临床观察

目的研究吉西他滨(健择,Gemcitabine,GEM)与顺铂(Cisplatin,PDD)组成的GP方案治疗晚期非小细胞肺癌(NSCLC)的疗效和毒性反应.方法 19例Ⅲ～Ⅳ期NSCLC患者,均经病理组织学和(或)细胞学确诊,治疗剂量:GEM 1000～1250 mg/m2,静滴第1、8天;DDP 80 mg/m2,静滴第1天(或分3～5 d给药),做适当水化利尿,21 d为1周期,2～3周期为1疗程.结果 19例患者中,CR 0例,PR 9例,有效率47.4%(9/19).中位缓解期8.0个月,中位生存期9.6个月.1年生存率47.4%(9/19).最主要的毒副反应为白细胞及血小板降低,但均可耐受.结论 GP方案治疗晚期非小细胞肺癌有较高的有效率和较长的生存期,毒性可以耐受.

GP regimen for treating advanced non-small cell lung cancer

Objective To evaluate the curative and side effects of gemcitabine(GEM) and cisplatin(DDP) regimen for treating advanced non-small cell lung cancer (NSCLC).Methods Nineteen patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study.The patients received GEM 1000-1250 mg/m2 on d1,8 and DDP 80 mg/m2 on d1 (or divide 3-5days) of 21-day cycle. Curative and side effects were evaluated after two to three cycles were completed.Results Complete remission (CR) was observed in 0 case and PR in 9 cases.The total response rate was 47.4%.The main side effects were leucopenia and thrombasthenia,but they were acceptable.Conclusion The combined regimen of GEM and DDP for treating advanced NSCLC has a high response rate and tolerable side effects.